<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486391</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-314</org_study_id>
    <secondary_id>CTR20201517</secondary_id>
    <nct_id>NCT04486391</nct_id>
  </id_info>
  <brief_title>Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of tislelizumab in
      participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by
      Progression-free Survival (PFS) as assessed by investigator
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 17, 2020</start_date>
  <completion_date type="Anticipated">March 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response (CR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>The proportion of participants who achieves a best overall response of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) by Investigator</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Time from the date of randomization to the time the response criteria are first met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 45 months</time_frame>
    <description>Defined as the time from the date of randomization to the date of death due to any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 45 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tislelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tislelizumab monotherapy for up to 45 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salvage chemotherapy for up to 45 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200 mg administered via intravenous (IV) infusion once every 3 weeks</description>
    <arm_group_label>Tislelizumab</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvage Chemotherapy</intervention_name>
    <description>Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)</description>
    <arm_group_label>Salvage chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria :

          1. Histologically confirmed cHL.Must have relapsed or refractory ( cHL and

               1. Has failed to achieve a response or progressed after autologous hematopoietic
                  stem cell transplant (ASCT). or

               2. Has received at least two prior lines of systemic chemotherapies for cHL and is
                  not an ASCT candidate.

          2. Must have measurable disease d3. Eastern Cooperative Oncology Group (ECOG) performance
             status of 0 or 1.

          3. Must have adequate organ functions.

          4. Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy used to
             control cancer including locoregional treatment must have been completed â‰¥ 4 weeks
             before the first dose of study drug, and all treatment-related adverse events are
             stable and have either returned to baseline or Grade 0/1

        Key Exclusion Criteria :

          1. Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma. Known central
             nervous system (CNS) lymphoma.

          2. Prior allogeneic hematopoietic stem cell transplant. ASCT or Chimeric Antigen Receptor
             T-Cell Immunotherapy (CAR-T) within 100 days of first dose of study drug.

          3. Prior therapies targeting PD-1 or PD-L1.

          4. Prior malignancy within the past 3 years except for curatively treated basal or
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
             cervix or breast.

          5. Participant with active autoimmune disease or history of autoimmune disease with high
             risk of recurrence.

          6. Serious acute or chronic infection requiring systemic therapy.

          7. Known human immunodeficiency virus (HIV), or serologic status reflecting active
             hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liudi Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

